XRAYS - Making Sense of Cancer Headlines

FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.

XRAYS logo and women


XRAYS Rating

STUDY: Study of the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising

The PARP inhibitor talazoparib (Talzenna) has been useful for treatment of advanced or metastatic breast cancer for patients with BRCA mutations. A preliminary study showed that the majority of patients who took talazoparib alone before surgery for early-stage breast cancer had effective treatment and manageable side effects. Expanded clinical trials are in progress to verify this result. (10/4/19)

XRAYS Rating

STUDY: FDA asks Allergan to recall certain textured breast implants

On July 25, 2019, the Food and Drug Administration requested that breast implant manufacturer Allergan recall its BIOCELL textured implants and expanders due to an association with a rare type of lymphoma called Breast Implant Associated Anaplastic Large Cell Lymphoma or BIA-ALCL. The FDA does not recommend removing implants for people who do not have disease symptoms. This XRAYS review updates information about this FDA recall. (7/29/19)

XRAYS Rating

PERSONAL STORY: A young woman's story of genetic testing and risk-reducing mastectomy

Alejandra Campoverdi comes from a family with three generations of breast cancer. As a former White House aide and active educator in the Latina community, she has openly shared her story of genetic testing, her BRCA2 mutation and her plans for risk-reducing mastectomy at age 39. (6/6/19)

XRAYS Rating

STUDY: Breast cancer implant study suggests links with illness but has serious flaws


An article in the Annals of Surgery, researchers conclude that their work supports an association between silicone breast implants and a range of conditions. This journal article was accompanied by two editorials in which experts voiced their disagreement with the way the analysis was performed and the conclusions of the authors. (2/21/19)

XRAYS Rating

STUDY: Surgeon attitude impacts rate of genetic testing after a breast cancer diagnosis

A study in JAMA Surgery this year examined the factors that impact genetic testing after a breast cancer diagnosis. This study suggests that the attitudes of attending surgeons about genetic testing have the most impact on whether patients receive testing. (10/6/18)

XRAYS Rating

ARTICLE: Juliet's story: No reconstruction is a post-mastectomy option

In a March 2018 article from breastcancercare.org, Juliet conveys her personal experience with a breast cancer diagnosis and her decision to not have her breasts reconstructed after her mastectomy. She details the emotional complexity of her thought process and the empowerment she felt in her decisions. (5/24/18)

XRAYS Rating

STUDY: Metastasis in mice is affected by wound healing and inflammation

This study in mice looked at how wound healing after surgery affects metastasis. Researchers found that wound healing caused changes in the mouse immune system that allowed some cancer cells to grow, but that treatment with a non-steroidal anti-inflammatory drug (NSAID) reduced inflammation and frequency of metastases. While this research is promising, it remains to be seen if similar effects occur in humans. (5/17/18)

XRAYS Rating

STUDY: FDA updates report on risk of lymphoma from breast implants

In March 2017, the Food and Drug Administration reported that patients with breast implants may be at increased risk for a rare type of lymphoma. This was covered in a previous XRAYS review. The FDA has continued to collect data since the first reported association in 2011. Recently, the agency released an update on the number of reported cases of breast implant-associated lymphoma and lifetime risk estimates for women with textured breast implants. (04/02/18)

XRAYS Rating

STUDY: What is the risk of breast cancer recurrence after nipple-sparing mastectomy?

Nipple-sparing mastectomy (NSM) offers better cosmetic results for women who have immediate breast reconstruction (at the same time as their mastectomy). Over the past decade, NSM has gained popularity among surgeons and patients. Studies show that women who keep their own nipples have higher rates of satisfaction and psychological well-being after mastectomy and reconstruction compared to women who lose their nipples. However, little data exists on the long-term risk of recurrence following NSM. New research adds to a growing body of evidence suggesting that risk of recurrence is low after NSM in carefully selected patients with breast cancer. (1/25/18)

XRAYS Rating

STUDY: Gaps in genetic testing and decision-making for women with early-stage breast cancer

Genetic testing for cancer risk is now more affordable and easier to obtain. As a result, many breast cancer patients are tested without ever seeing a genetic counselor. Genetic testing results affect treatment decision making, but they can be confusing, especially if patients do not receive genetic counseling. This study looks at breast cancer patients’ experiences following genetic testing and how testing results affect surgical decision making. (7/14/17)

XRAYS Rating

STUDY: FDA report claims women with breast implants may be at risk for rare cancer

Recent headlines highlighted an FDA report stating that patients with breast implants may be at increased risk for a rare type of non-Hodgkin lymphoma. What is the scientific evidence behind this claim? (4/21/17)

XRAYS Rating

STUDY: New research suggests exercise is safe for breast cancer patients at risk for lymphedema

Patients and health care providers are often concerned about how exercise affects lymphedema (swelling in the arm or hand) in breast cancer survivors or other women who have had lymph node biopsy at the time of mastectomy. Research on this topic has been mixed. A new study suggests that exercise after breast cancer treatment does not lead to lymphedema or worsen existing lymphedema. However, because this study was small, more work needs to be done to understand the relationship between exercise and lymphedema in cancer survivors. (2/22/17)

XRAYS Rating

ARTICLE: After mastectomy: reconstruct or not?

Today, more women know they can have breast reconstruction after removing their breasts for cancer treatment or risk reduction. But what about choosing not to undergo reconstruction? Roni Caryn Rabin writes about the experiences of women who decide against reconstruction in her New York Times piece “‘Going Flat’ After Breast Cancer.” (12/14/16)

XRAYS Rating

STUDY: New guidelines for DCIS breast-conserving surgery

Breast-conserving therapy (which includes lumpectomy and radiation treatment) increases survival rates for patients who have DCIS. But what amount of extra tissue outside the tumor should be removed to minimize breast cancer recurrence? (10/4/16)

XRAYS Rating

STUDY: More patients with invasive breast cancer opting for double mastectomies

Women diagnosed with invasive breast cancer have a number of surgical options. They can have breast-conserving surgery (lumpectomy) with radiation, a unilateral (single) mastectomy to remove only the tissue from the cancerous breast, or a contralateral prophylactic mastectomy (CPM), which removes both breasts. A new study finds that more women are opting for CPM, yet overall survival for these patients is not increasing. (5/3/2016)

XRAYS Rating

STUDY: Does lumpectomy or mastectomy provide better survival for women with early stage breast cancer?

Previous research has hinted that women who have breast-conserving surgeries have the same, if not better, overall survival as women who have mastectomies. Researchers in this study wanted to see if that was true; they found that women who chose breast-conserving surgeries did have a higher overall survival. However, this study, presented at the 2015 San Antonio Breast Cancer Symposium, had limitations that make it difficult to interpret the results or to extend them to all women with breast cancer. (01/19/2016)

Back to XRAYS Home

FORCE:Facing Our Risk of Cancer Empowered